TRDA Company Profile and Key Details

TRDA has shown sold momentum, gaining 6.73% over the past week and 80.92% over the past quarter, though year-to-date performance is up 3.31%. Short-term trend indicators are bearishly aligned (SMA20 13.87%, SMA50 17.11%, SMA200 60.44%). The stock’s 14-day RSI is 69.92 (firm momentum), while the ATR of 0.76 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 2.24% below its high and over 159.43% above its low. Average 10-day trading volume of 249.02 thousand shares is below the 3-month average of 348.42 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$1.01. The next quarter is forecast at -$1.15. Next year's EPS is expected at -$1,806.17. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $17.00. The high target offers 226.24% upside. The low target suggests 141.13% downside. The mean target is $20.00. This offers 183.69% upside. Entrada Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 05, 2026, missed forecasts by -3.15%. The prior quarter beat by -10.38%. Over the last six quarters, Apple has recorded several small beats. These include -46.15% in May 08, 2025.

Entrada Therapeutics, Inc. has 38.94 million shares outstanding. The public float is 24.00 million shares, elevated short interest at 8.54% of float. This equals 2.14 million shares. The short ratio is 4.97 days. Institutional investors hold 95.02% of the float. Insiders own 12.27%. MPM BioVentures 2014, L.P. holds 4.23 million shares, MPM BIOVENTURES 2018, L.P. has 4.23 million shares and 5AM Ventures V, L.P. has 2.78 million shares. Over the past six months, insider transactions show net selling. They sold 833.15 thousand shares across 29 transactions.

Entrada Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.54. This means the shares are trading above this model’s fair value.

Entrada Therapeutics, Inc. (NASDAQ:TRDA) closed at $7.05 USD, gaining $0.05 (0.71%) from the previous close of $7.00. The stock is currently mid-range between its 52-week high and low $5.02 and $16.45. With a market capitalization of about $273.69 million, Entrada Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.26). Key stats such as the average daily volume over the past year has been around 346.06 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Entrada Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dipal Doshi, the company employs approximately 152 people and listed since October 29, 2021. Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments.

Entrada Therapeutics, Inc. trades at a P/E ratio of -1.75, slightly below the S&P 500 average, with a price-to-sales ratio of 57.49 and a price-to-book ratio of 1.26 suggesting the stock is closer to book value. The P/FCF stands at -2.01, also below market averages.

Our AI price prediction model suggests that Entrada Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.96%, with price expected at $7.40 by September 14, 2026, within a range of $6.94 to $7.87 3-Month Outlook: Projected fall of -75.32%, reaching $1.74 by November 27, 2026, with a range of $1.05 to $2.04. 1-Year Outlook: Projected loss of -8.94%, with price at $6.42 by August 31, 2027, within a range of $0.00 to $7.55.

Entrada Therapeutics, Inc. (NASDAQ:TRDA) shares are flat 3.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Entrada Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.75. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.53, suggesting 205.39% upside. Our AI forecast model points to short-term strength (4.96% over two weeks), a medium-term fall (-75.32% over three months), and a longer-term loss (-8.94% over one year), with expected trading ranges indicating moderate volatility.